Skip to main content
    C

    Cytokinetics Inc (CYTK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $51.65
    -1.52 (-2.86%)

    Market Cap: $7.82B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Cytokinetics Inc (CYTK) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Cytokinetics (CYTK) has a market cap of $7.82B and an enterprise value of $8.77B. It kept -686.63% of revenue as net income over the last 12 months. Its share count is up 15.89% from a year earlier.

    Total Valuation

    Enterprise value is 12.13% above the market cap, as debt exceeds cash.

    Market Cap$7.82B
    Enterprise Value$8.77B
    Latest price (Nov 17, 2026)$51.65

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 5.27% in the quarter ended Sep 30, 2026 and grew 8.70% a year over 2 years.

    Shares Outstanding139.04M
    Shares Change (YoY)+15.89%
    Shares Change (QoQ)+5.27%
    Share Count Growth (2Y CAGR)+8.70%

    Valuation Ratios

    The price to sales ratio is 63.4x. Its year-end P/S ranged from 4.7x to 298.5x from 2016 to 2025.

    P/S Ratio63.4x
    Forward P/S47.5x

    Price Statistics

    The stock is down 22.26% over 52 weeks and trades 18.34% below its 50-day average.

    Beta (1Y)1.07
    52-Week Change-22.26%
    1-Month Change-17.56%
    3-Month Change-33.56%
    6-Month Change-32.44%
    5-Year Change+80.44%
    10-Year Change+549.38%
    Total Return (1Y)-22.26%
    Total Return (3Y CAGR)+16.77%
    Total Return (5Y CAGR)+4.87%
    Return vs SPY (1Y)-33.49%
    Max Drawdown (1Y)-40.81%
    Max Drawdown (3Y)-72.39%
    Sharpe Ratio (1Y)-0.57
    Correlation with SPY (1Y)0.34
    50-Day Average$63.25
    200-Day Average$69.66
    52-Week Range$52.68 to $88.31
    RSI (14 Days)30.7
    Average Volume (20 Days)2.07M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.36x current liabilities.

    Current Ratio3.36x
    Quick Ratio3.36x
    Interest Coverage-5.06x

    Returns and Efficiency

    Return on invested capital is -65.96% over the last 12 months.

    Return on Assets (ROA)-42.63%
    Return on Invested Capital (ROIC)-65.96%
    Return on Capital Employed (ROCE)-47.12%
    ROA (5Y Average)-44.98%
    Asset Turnover0.07x
    Receivables Turnover3.89x

    Scores

    CYTK has an Altman Z-Score of -1.77, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-1.77
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $113.29M over the last 12 months is up 29.53% from the 12 months before.

    Revenue$113.29M
    Revenue Growth (YoY)+29.53%
    Gross Profit$105.60M
    Operating Income-$708.24M
    Pretax Income-$830.23M
    Net Income-$777.89M
    EBITDA-$693.31M
    EBIT-$693.24M
    Reported EPS (TTM)-$6.04

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$203.43M
    Total Debt$1.15B
    Net Debt$948.07M
    Net Debt Per Share$6.82
    Working Capital$833.73M
    Shareholder Equity-$321.17M
    Total Assets$1.82B
    Total Liabilities$2.15B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $16.61M of capital spending, operating cash flow left -$588.58M of free cash flow.

    Operating Cash Flow-$571.97M
    Capital Expenditures$16.61M
    Free Cash Flow-$588.58M
    FCF Per Share-$4.23
    Depreciation and Amortization$27.10M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -625.15%.

    Gross Margin93.21%
    Operating Margin-625.15%
    Pretax Margin-732.83%
    Net Margin-686.63%
    EBITDA Margin-611.97%
    EBIT Margin-611.91%
    FCF Margin-519.53%

    Growth

    Revenue fell 2.36% a year over 3 years.

    Revenue Growth (3Y CAGR)-2.36%
    Revenue Growth (5Y CAGR)+9.54%

    Revenue and profit by year

    Dividends and Yields

    CYTK does not pay a dividend. Its free cash flow yield is -8.20%.

    FCF Yield-8.20%
    Buyback Yield-11.65%
    Shareholder Yield-11.65%

    Stock Splits

    The last split was a 1-for-6 reverse split on Jun 25, 2013.

    Last Split DateJun 25, 2013
    Split TypeReverse split
    Split Ratio1:6

    Peer Position

    Against 5 similar companies, CYTK has the 2nd highest P/S.

    P/S Ratio63.4x vs 18.8x median
    ROIC-65.96% vs -43.38% median
    Revenue Growth (Trailing 4 Quarters, YoY)+29.53% vs +61.04% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 124.35% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+124.35%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CYTK

    What is CYTK's market cap?

    Cytokinetics has a market cap of $7.82B. Its enterprise value, which adds debt and subtracts cash, is $8.77B.

    How many shares of CYTK are outstanding?

    Cytokinetics has 139.04M shares outstanding. The count is up 15.89% from a year earlier.

    Does CYTK pay a dividend?

    No. Cytokinetics does not pay a dividend.

    How much debt does CYTK have?

    Cytokinetics has $1.15B of total debt and $203.43M of cash and equivalents, a net debt position of $948.07M.